News
URGN
40.97
-3.60%
-1.53
Weekly Report: what happened at URGN last week (0720-0724)?
Weekly Report · 4h ago
Biotech stocks lead healthcare's overbought list as earnings picks up
Seeking Alpha · 4d ago
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
TipRanks · 5d ago
UroGen Pharma Is Maintained at Buy by Guggenheim
Dow Jones · 6d ago
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42
Benzinga · 6d ago
UroGen Pharma price target raised to $42 from $32 at Guggenheim
TipRanks · 6d ago
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat
Seeking Alpha · 6d ago
Weekly Report: what happened at URGN last week (0713-0717)?
Weekly Report · 07/20 10:17
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027
Barchart · 07/17 09:15
UroGen Pharma Is Maintained at Outperformer by Oppenheimer
Dow Jones · 07/16 15:07
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50
Benzinga · 07/16 14:57
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
TipRanks · 07/16 12:21
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Urogen Pharma (URGN)
TipRanks · 07/16 12:01
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)
TipRanks · 07/16 10:50
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
TipRanks · 07/15 21:15
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
TipRanks · 07/15 21:10
UroGen Receives USPTO Notice Of Allowance For Patent Covering Treatment Of Recurrent LG-IR-NMIBC With Thermally Gelling Mitomycin; Claims Supported By ENVISION And ATLAS Trials, Patent To Expire July 2044
Benzinga · 07/15 12:02
Weekly Report: what happened at URGN last week (0706-0710)?
Weekly Report · 07/13 10:19
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)
TipRanks · 07/09 10:40
UroGen Pharma announces FDA clearance for UGN-501 IND application
TipRanks · 07/08 12:05
More
Webull provides a variety of real-time URGN stock news. You can receive the latest news about Urogen Pharma through multiple platforms. This information may help you make smarter investment decisions.
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).